Introduction: This study is aimed at investigating the olfactory function among different subtypes of Parkinson disease (PD) and the impact of sex on smell identification test. Methods: In this cross-sectional study, we used Iran-smell identification test (Iran-SIT). PD severity was determined using a Hoehn and Yahr (H&Y) scale. We used analysis of covariance (ANCOVA) to compare the olfactory function among different PD subtypes. All analyses were performed using SPSS software version 16.0. Results: In total, 66 males and 38 females participated in this study. The most common PD subtype was postural instability and gait difficulty (38.5%). Severe hyposmia and anosmia were found in 44.6 and 19.6% of participants, respectively. Women had a higher score in olfactory function than men (p = 0.44). The score of subjects with stage 1 in the H&Y scale was about 3 points higher than the score with stage 4. The ANCOVA showed a statistically significant effect of subtypes PD on Iran-SIT score after controlling for the effects of covariates (p = 0.03). There is a significant difference between tremor-dominant Parkinson disease (TDPD) and other subtypes of PD (p < 0.05). However, Iran-SIT scores failed to show a significant difference between men and women (p = 0.13). Discussion/Conclusion: Our results confirmed that PD is heterogeneous and there is significant variability in odor identification ability in these patients. We observed more olfactory impairment in TDPD, and subjects with higher H&Y stage. We recommended future studies with repeated measurements of different aspects of smell function to characterize the temporal relationship of olfactory dysfunction with PD.

Keywords:
Parkinson disease, Smell, Iran smell identification test, Olfaction disorder
1.
Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease.
Nat Rev Neurosci
. 2017 Jul;18(7):435–50.
2.
Hinnell C, Chaudhuri KR. The effect of non-motor symptoms on quality of life in Parkinson’s disease.
Eur Neurol Rev
. 2009;4(2):29–33.
3.
Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management.
Lancet Neurol
. 2006 Mar;5(3):235–45.
4.
Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, et al. Research on the premotor symptoms of Parkinson’s disease: clinical and etiological implications.
Environ Health Perspect
. 2013 Nov-Dec;121(11–12):1245–52.
5.
Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A. Neurochemistry and the non-motor aspects of PD.
Neurobiol Dis
. 2012 Jun;46(3):508–26.
6.
Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, et al. Biopsies of olfactory epithelium in patients with Parkinson’s disease.
Mov Disord
. 2009 Apr;24(6):906–14.
7.
Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, et al. Neuropathology of non-motor features of Parkinson disease.
Parkinsonism Relat Disord
. 2009 Dec;15(suppl 3):S1–5.
8.
Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex.
Neurosci Lett
. 2009 Apr;453(2):77–80.
9.
Mundiñano IC, Caballero MC, Ordóñez C, Hernandez M, DiCaudo C, Marcilla I, et al. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders.
Acta Neuropathol
. 2011 Jul;122(1):61–74.
10.
Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, et al. Prevalence of smell loss in Parkinson’s disease–a multicenter study.
Parkinsonism Relat Disord
. 2009 Aug;15(7):490–4.
11.
Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH, et al. Is normosmic Parkinson disease a unique clinical phenotype?
Neurology
. 2015 Oct;85(15):1270–5.
12.
Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease.
Mov Disord
. 2012 Apr;27(5):617–26.
13.
Thenganatt MA, Jankovic J. Parkinson disease subtypes.
JAMA Neurol
. 2014 Apr;71(4):499–504.
14.
Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S, et al. Differences in odor identification among clinical subtypes of Parkinson’s disease.
Eur J Neurol
. 2011 Mar;18(3):425–9.
15.
Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, et al. Olfactory function in Parkinson’s disease subtypes.
Neurology
. 1994 Feb;44(2):266–8.
16.
Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, et al. The new definition and diagnostic criteria of Parkinson’s disease.
Lancet Neurol
. 2016 May;15(6):546–8.
17.
Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al.; Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.
Mov Disord
. 2004 Sep;19(9):1020–8.
18.
Taherkhani S, Moztarzadeh F, Mehdizadeh Seraj J, Hashemi Nazari SS, Taherkhani F, Gharehdaghi J, et al. Iran Smell Identification Test (Iran-SIT): a Modified Version of the University of Pennsylvania Smell Identification Test (UPSIT) for Iranian Population.
Chemosens Percept
. 2015;8(4):183–91.
19.
Hawkes CM. Diagnosis and treatment of Parkinson’s disease. Anosmia is a common finding.
BMJ
. 1995 Jun;310(6995):1668.
20.
Haugen J, Müller ML, Kotagal V, Albin RL, Koeppe RA, Scott PJ, et al. Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation.
J Neural Transm (Vienna)
. 2016 Apr;123(4):421–4.
21.
Hong JY, Chung SJ, Lee JE, Sunwoo MK, Lee PH, Sohn YH. Predictive value of the smell identification test for nigrostriatal dopaminergic depletion in Korean tremor patients.
Parkinsonism Relat Disord
. 2013 Nov;19(11):1018–21.
22.
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al.; Amyloid Biomarker Study Group. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
JAMA
. 2015 May;313(19):1924–38.
23.
Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease.
Ann Neurol
. 2008 Feb;63(2):167–73.
24.
Zhang C, Wang X. Initiation of the age-related decline of odor identification in humans: A meta-analysis.
Ageing Res Rev
. 2017 Nov;40:45–50.
25.
Haehner A, Hummel T, Reichmann H. Olfactory loss in Parkinson's disease. Parkinson’s Disease. 2011;2011:450939.
26.
Haehner A, Hummel T, Reichmann H. A clinical approach towards smell loss in Parkinson’s disease.
J Parkinsons Dis
. 2014;4(2):189–95.
27.
Liu R, Umbach DM, Peddada SD, Xu Z, Tröster AI, Huang X, et al. Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease.
Neurology
. 2015 May;84(21):2107–15.
28.
Katotomichelakis M, Balatsouras D, Tripsianis G, Davris S, Maroudias N, Danielides V, et al. The effect of smoking on the olfactory function.
Rhinology
. 2007 Dec;45(4):273–80.
29.
Frye RE, Schwartz BS, Doty RL. Dose-related effects of cigarette smoking on olfactory function.
JAMA
. 1990 Mar;263(9):1233–6.
30.
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease.
Mov Disord
. 2006 Aug;21(8):1123–30.
31.
Aleksovski D, Miljkovic D, Bravi D, Antonini A. Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci. 2018 Nov;39(11):1971–6.
32.
Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators. How stable are Parkinson’s disease subtypes in de novo patients: analysis of the PPMI cohort?
Parkinsonism Relat Disord
. 2016 Jul;28:62–7.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.